By Christine Cleary The 21st century has seen great strides in treatment for multiple myeloma, a cancer of the bone marrow once considered a death sentence. In fact, thanks to research by Dana-Farber scientists, this blood cancer that took the lives of Geraldine Ferraro and Leonard P. Zakim has become a chronic disease for many patients.
What is different and special about Dana-Farber/Brigham and Women’s Cancer Center? Several doctors and nurses answer this question in a new advertising campaign. The campaign promotes the specialized care and team approach provided in Boston and at regional care centers in South Weymouth and Milford, Mass. Behind DF/BWCC patient care is a team that collaborates with one another and accompanies patients through their cancer journey, the ads show. The campaign consists of three television ads as well as radio and print advertising. The theme of “You have us” carries through all media, encouraging viewers to “Take the first step together” with …
By Melanie Graham During a child’s cancer therapy and recovery process, insomnia can often be viewed as only a side effect in the scope of treatment-related symptoms. However, there are many physical and psychological implications that develop when a child does not sleep well, says Eric Zhou, PhD, a clinical psychology fellow in Dana-Farber’s David B. Perini, Jr. Quality of Life Clinic. Zhou, who is also a research fellow at Harvard Medical School, has spent the last year studying treatments for insomnia in adolescent and young adult cancer survivors through Dana-Farber’s Swim Across America Fellowship.
More than 70 years ago, two pharmacologists began looking at mustard gas as a possible treatment for lymphoma. The chemical, used during World War I, lowered blood counts and destroyed lymph nodes in soldiers who were exposed to the gas. Two decades after the war, a thoracic surgeon named Gustav Lindskog used nitrogen mustard to successfully treat a patient with non-Hodgkin’s lymphoma.
By Lori Buswell, RN I recently returned from a three-month rotation as a nurse fellow at a comprehensive cancer center at Butaro Hospital in Rwanda, a tiny African country known as the “land of a thousand hills.” The hospital, built and operated by the Ministry of Health and Partners In Health, is located in a rural, mountainous area where most residents are farmers. Because most homes do not have running water, people fill up 5-gallon jugs at the local water spigot.
Liz Moroney celebrated her 23rd birthday in an unusual place — at a fertility clinic. Liz, a recent college graduate, wanted to plan for having children before it was too late. Diagnosed with Hodgkin’s lymphoma in June 2010, she spent 4 months in chemotherapy treatment in New York. Afterward, she and her reproductive endocrinologist watched her fertility numbers dwindle over a year of visits. Her endocrinologist was skeptical of the effectiveness of fertility treatment; So, too, was Liz.
The drug Avastin, when added to initial therapy for glioblastoma, can give patients a few extra months’ reprieve before their brain tumors start growing again, but does it make their quality of life better – or worse? That’s a matter of heated debate for doctors – and confusion for patients – after two large clinical trials reported conflicting results at the annual American Society of Clinical Oncology (ASCO) conference in June. Some experts contend that Avastin lacked sufficient benefit for use as an “upfront” treatment for glioblastomas – the most common and aggressive brain tumors.